Journal article

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer - The urologists' perspective

Jo-Lynn Tan, Niranjan Sathianathen, Nicolas Geurts, Rajesh Nair, Declan G Murphy, Alastair D Lamb

UROLOGICAL SCIENCE | WOLTERS KLUWER MEDKNOW PUBLICATIONS | Published : 2017

Abstract

Androgen deprivation therapy (ADT), which involves the maximal suppression of circulating testosterone, underpins the treatment approach to metastatic hormone sensitive prostate cancer. Although initial responses are generally favourable, approximately half of cases progress to metastatic castrate resistant prostate cancer (mCRPC), rendering traditional hormonal therapies ineffective. mCRPC is defined by disease progression despite established ADT. New research has improved our understanding of the the molecular mechanisms behind metastatic castration-resistant prostate cancer (mCRPC). This has led to a renewed interest in the androgen receptor as a target for therapy, paving the way for the..

View full abstract